Bacterium Or Component Thereof Or Substance Produced By Said Bacterium (e.g., Legionella, Borrelia, Anaplasma, Shigella, Etc.) Patents (Class 424/234.1)
  • Patent number: 10679725
    Abstract: The present invention relates to a combination of experimental and computational workflows that allow characterization of specific molecular mechanisms by which the microbiome contribute to skin health and skin age.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: June 9, 2020
    Assignee: PRODERMIQ, INC.
    Inventors: Dana Hosseini, Sasan Amini, Eveie Schwartz
  • Patent number: 10668136
    Abstract: The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular Lactococcus lactis, of secreted immunodominant antigens.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: June 2, 2020
    Assignee: INTREXON ACTOBIOTICS NV
    Inventors: Pieter Rottiers, Veerle Snoeck
  • Patent number: 10646559
    Abstract: The present invention provides antigens, for use in the treatment or prevention of C. burnetii infection. Also provided are nucleic acids encoding such antigens, and antibodies raised against such antigens.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: May 12, 2020
    Assignee: SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE
    Inventors: Julia Vipond, Kevin Bewley
  • Patent number: 10548917
    Abstract: Embodiments of a method and supplement for preventing and/or treating gastrointestinal distress, including ulcer conditions, in animals are disclosed. The supplement comprises mastic gum and an emulsifying agent such as lecithin. The supplement may also comprise B vitamins, one or more prebiotics or probiotics, and one or more minerals as well as, pH buffers and flavoring. A disclosed method of preventing and/or treating gastrointestinal distress comprises orally dosing an animal with the supplement at least one daily.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: February 4, 2020
    Assignee: KAECO Group Inc.
    Inventors: Kelly Terry, Leon Kratochvil, James Harless, Tom Kratochvil
  • Patent number: 10494684
    Abstract: A spore-forming Bacillus species, and more particularly, a Bacillus subtilis strain identified as MB40 is provided. Compositions comprising the MB40 strain, methods of making products comprising the same, and methods of using the same are also provided.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: December 3, 2019
    Assignee: BIO-CAT, INC.
    Inventors: Christopher S. Penet, Sebhat Gebrechristos, Caroline Helen Best, Deborah S. Winetzky, Robert Daniel Little, Jr., Jessica Spears, Christopher Schuler
  • Patent number: 10441645
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: October 15, 2019
    Assignee: VAXIMM GMBH
    Inventors: Marco Springer, Heinz Lubenau
  • Patent number: 10406184
    Abstract: Provided is a composition for preventing, ameliorating, or treating inflammatory diseases, the composition including, as active ingredients, lactic acid bacteria-derived extracellular vesicles isolated from culture fluid of lactic acid bacteria; and a method for diagnosing atopic dermatitis. The composition including the lactic acid bacteria-derived extracellular vesicles as active ingredients is expected to be usefully used in development of drugs, cosmetics, or health functional food for preventing, ameliorating, or treating inflammatory diseases such as atopic dermatitis, chronic rhinitis, chronic rhinosinusitis, asthma, chronic obstructive pulmonary disease, sepsis, etc. Also, the composition will be usefully used for diagnosis of atopic dermatitis by measuring the distribution of lactic acid bacteria-derived extracellular vesicles in a urine or blood sample.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: September 10, 2019
    Assignee: MD HEALTHCARE INC.
    Inventors: Yoon-Keun Kim, Bok Yang Pyun, Minhye Kim, Jun-Pyo Choi
  • Patent number: 10336794
    Abstract: Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titres than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: July 2, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Jeannette Adu-Bobie, Mariagrazia Pizza, Nathalie Norais, Germano Ferrari, Guido Grandi
  • Patent number: 10335476
    Abstract: Certain embodiments are direct to a vaccine composition comprising an immunizing amount of an Ehrlichia sonicate, wherein the Ehrlichia sonicate elicits a protective physiologic response. In certain aspects the Ehrlichia is one or more of E. canis, E. chaffeensis, E. muris, E. ruminantium, E. ewingii, and E. ovis.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: July 2, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Sunil Thomas, David H. Walker
  • Patent number: 10324090
    Abstract: This disclosure provides a method for detecting infection of an animal by Mycobacterium bovis. The method generally includes obtaining a biological sample from a host animal at risk of being infected by Mycobacterium bovis and analyzing the sample for the presence or absence of at least one M. bovis polypeptide. In some embodiments, the method can further include analyzing the sample for the presence or absence of at least one M. bovis lipid. In some embodiments, the method can further include detecting at least one host polypeptide whose expression is greater in a host infected with M. bovis compared to expression in a host known to be uninfected with M bovis.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: June 18, 2019
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Srinand Sreevatsan, Elise Lamont
  • Patent number: 10232026
    Abstract: Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma-mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria. Bacterium-mimic particles such as mycoplasma-mimic particles can be provided by producing liposome particles in which a lipid antigen specific to a pathogenic bacterium such as mycoplasma is contained as a liposome-constituting lipid component. The administration of the mycoplasma-mimic particles enables the induction of a potent immunological activity in living bodies. The mycoplasma-mimic particles can be used as an excellent vaccine for the prevention or treatment of mycoplasma infection.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: March 19, 2019
    Assignees: NATIONAL INSTITUTE OF INFECTIOUS DISEASES, M BIO TECHNOLOGY INC.
    Inventors: Kazuhiro Matsuda, Koji Ichiyama, Sachie Matsuda, Yuko Sasaki, Yoshichika Arakawa, Ryo Harasawa, Yoshihiro Nishida, Norio Katayama, Yasuo Endo, Nobuo Nomura
  • Patent number: 10195259
    Abstract: Provided herein are compositions comprising substantially non-viable Gram-negative bacterial organisms that have a substantial reduction in endotoxin activity and/or pyrogenicity and methods for treating a cancer using the same. Also provided are methods for treating cancer provided herein, comprising administering to a mammal diagnosed with cancer, substantially non-viable Gram-negative bacteria having a substantial reduction in endotoxin activity and/or pyrogenicity, in an amount sufficient to inhibit growth or metastasis of the cancer. An additional method is provided comprising administering viable or non-viable Gram-negative bacterial organisms that have a genetic defect that results in a substantial loss of lipopolysaccharide within the outer membrane of the bacteria. Further provided are methods for reducing endotoxin activity and/or pyrogenicity in Gram-negative bacteria comprising treatment with polymyxin and glutaraldehyde.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: February 5, 2019
    Assignee: Decoy Biosystems, Inc.
    Inventor: Michael J. Newman
  • Patent number: 10188733
    Abstract: The present invention demonstrates that bisphosphonates have an intrinsic adjuvant activity and directly stimulate B cell antibody secretion. Accordingly, the present invention provides vaccines comprising a bisphosphonate, methods for stimulating an immune response, enhancing the immunogenicicty of an immunogen, and methods of treating an infection, an autoimmune disease, an allergy, and/or a cancer using the same.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: January 29, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: Ulrich H. von Andrian, Matteo Iannacone, Elena Tonti, Elliott Ashley Moseman
  • Patent number: 10166186
    Abstract: The invention relates to a method for producing a nutritional and medicinal oral composition for veterinary use, comprising the following steps: a) providing cores of extruded products of complete feed, and b) coating the cores of extruded products of complete feed provided in step a) with at least one layer of a fatty material comprising at least one medicinal agent, said medicinal agent comprising (i) at least one pre-conditioned active substance in the form of a solution or a suspension of said active substance in an oily liquid, or (ii) at least one pre-conditioned active substance in the form of waxy granulates, at a temperature lower than 40° C.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: January 1, 2019
    Assignee: VIRBAC
    Inventors: Nicolas Brunel, Fanny Martins, Patricia Goisnard
  • Patent number: 10143736
    Abstract: This document relates to methods and materials for producing immune responses against polypeptides involved in antibiotic resistance. For example, vaccines against polypeptides involved in antibiotic resistance as well as methods for vaccinating mammals against polypeptides involved in antibiotic resistance are provided.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: December 4, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Michael A. Barry
  • Patent number: 10064930
    Abstract: The disclosure provides for immunogenic compositions against Pigeon Fever, and methods for their use and preparation. The immunogenic compositions, in alternate embodiments, also include other equine pathogens.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: September 4, 2018
    Inventors: Phillip Wayne Hayes, Kristina J. Hennessy
  • Patent number: 10052371
    Abstract: Provided herein are compositions comprising substantially non-viable Gram-negative bacterial organisms that have a substantial reduction in endotoxin activity and/or pyrogenicity and methods for treating a cancer using the same. Also provided are methods for treating cancer provided herein, comprising administering to a mammal diagnosed with cancer, substantially non-viable Gram-negative bacteria having a substantial reduction in endotoxin activity and/or pyrogenicity, in an amount sufficient to inhibit growth or metastasis of the cancer. An additional method is provided comprising administering viable or non-viable Gram-negative bacterial organisms that have a genetic defect that results in a substantial loss of lipopolysaccharide within the outer membrane of the bacteria. Further provided are methods for reducing endotoxin activity and/or pyrogenicity in Gram-negative bacteria comprising treatment with polymyxin and glutaraldehyde.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: August 21, 2018
    Assignee: Decoy Biosystems, Inc.
    Inventor: Michael J. Newman
  • Patent number: 10054586
    Abstract: Mycobacterial-specific biomarkers and methods of using such biomarkers for diagnosis of mycobacterial infection in a mammal are disclosed.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: August 21, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Adel M. Talaat
  • Patent number: 10023848
    Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides methods of inducing an immune response against a panton-valentine leukocidin (PVL)-expressing S. aureus, methods of preventing or treating S. aureus infections, and composition for preventing or treating S. aureus infections.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: July 17, 2018
    Assignee: INTEGRATED BIOTHERAPEUTICS, INC
    Inventors: Mohammad Javad Aman, Rajan Prasad Adhikari, Hatice Karauzum, Jawad Sarwar, Sergey Shulenin, Sathya Venkataramani, Kelly Lyn Warfield, Tam Luong Nguyen
  • Patent number: 10016493
    Abstract: Vaccines comprising TRAP polypeptides and Salmonella enteritidis vectors comprising TRAP polypeptides are provided. The vaccines may also include a CD154 polypeptide capable of binding to CD40. Also provided are methods of enhancing an immune response against Apicomplexan parasites and methods of reducing morbidity associated with infection with Apicomplexan parasites.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: July 10, 2018
    Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Walter Bottje, Billy Hargis, Luc Berghman, Young Min Kwon, Kimberly Cole, Mandy Cox, Sherryll Layton, Saeed El-Ashram, John Barta, Guillermo Tellez
  • Patent number: 10011662
    Abstract: The present invention relates to a novel process for purifying bacterial polysaccharide. It is an efficient and scalable process for removing impurities from Neisseria meningitidis serogroup C (Men-C) polysaccharide which is capable of being used as such in a derivatized form or linked to other molecules, for the preparation of vaccines, more particularly conjugate vaccines for N. meningitidis infection.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: July 3, 2018
    Assignee: MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD.
    Inventors: Davinder Gill, Manoj Kumar Chhikara, Sandeep Sharma, Sarmad Hanif, Neeraj Joshi
  • Patent number: 10004798
    Abstract: Provided herein are Salmonella enteritidis 13A strains and compositions comprising these strains. Also provided are methods of enhancing an immune response against Influenza A and methods of reducing morbidity associated with an Influenza A infection. Methods of enhancing an immune response to a vaccine vector by expressing a polypeptide of CD154 capable of binding CD40 are also disclosed. Methods of developing a bacterial vaccine vector are disclosed. Methods of generating scarless site-specific mutations in a bacterium are also disclosed.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: June 26, 2018
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Walter Bottje, Billy Hargis, Luc Berghman, Young Min Kwon, Kimberly Cole, Mandy Cox, Sherryll Layton
  • Patent number: 9988679
    Abstract: Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: June 5, 2018
    Assignees: University of Washington, The UAB Research Foundation
    Inventors: Jens H. Gundlach, Michael Niederweis, Thomas Z. Butler, Mikhail Pavlenok, Mark A. Troll, Suja Sukumaran
  • Patent number: 9976149
    Abstract: A Listeria bacterium is disclosed which comprises a first mutation in the multidrug resistance transporter M (MdrM) gene which causes a decrease in interferon-? production in macrophages as compared to wild-type Listeria bacterium and a second mutation in the multidrug resistance transporter T (MdrT) gene which causes a decrease in interferon-? production in macrophages as compared to the wild-type Listeria bacterium.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: May 22, 2018
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Anat Afriat Herskovits, Millie Kaplan Zeevi
  • Patent number: 9957511
    Abstract: Various aspects and embodiments of the present disclosure are directed to methods and compositions for functionalizing endogenous bacteria in vivo. The methods include delivering to endogenous bacterial cells a recombinant bacteriophage or phagemid that is engineered to contain at least one genetic circuit.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: May 1, 2018
    Assignees: Massachusetts Institute of Technology, Trustees of Boston University
    Inventors: Timothy Kuan-Ta Lu, Robert James Citorik, James Collins, Russell-John Krom
  • Patent number: 9878024
    Abstract: Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active Listeria that encodes an expressible antigen that is cross-reactive with the target antigen. In some examples, the immune response is a cellular immune response.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: January 30, 2018
    Assignee: ADURO BIOTECH, INC.
    Inventors: Thomas W. Dubensky, Jr., Dirk G. Brockstedt, Meredith Lai Ling Leong, Keith S. Bahjat
  • Patent number: 9855302
    Abstract: Provided herein are methods of treatment and/or prevention of cancer by manipulation of commensal microflora. In particular, the amount, identity, presence, and/or ratio of microflora (e.g., gut microflora) in a subject is manipulated to facilitate one or more co-treatments.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: January 2, 2018
    Assignee: The University of Chicago
    Inventors: Thomas F. Gajewski, Ayelet Sivan, Leticia Corrales
  • Patent number: 9796960
    Abstract: Provided is a method for preparing and using cell ghosts with active factors as a synergist of a lymphocyte in vitro culture. The method for preparing cell ghosts comprises: washing a cell to obtain a washed cell; and cleaving the washed cell to obtain cell ghosts, wherein the cell has cytokines capable of promoting the proliferation and differentiation of lymphocytes on their surface.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: October 24, 2017
    Inventor: Mingjie Zhang
  • Patent number: 9791440
    Abstract: The disclosure provides methods, compositions, and kits for enhanced detection of microbes in samples and monitoring of antimicrobial activity in a subject.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: October 17, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Mark J. Cartwright, Nazita Gamini, Donald E. Ingber, Martin Rottman, Michael Super, Julie A. Tomolonis, Karen A. Sinclair
  • Patent number: 9771399
    Abstract: Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titers than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: September 26, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Jeannette Adu-Bobie, Mariagrazia Pizza, Nathalie Norais, Germano Ferrari, Guido Grandi
  • Patent number: 9764020
    Abstract: The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: September 19, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Vega Masignani, Marirosa Mora, Maria Scarselli
  • Patent number: 9757438
    Abstract: Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: September 12, 2017
    Assignee: MICROVAX, LLC
    Inventors: Yucheng Tang, Albert Deisseroth
  • Patent number: 9751915
    Abstract: The invention relates to mutant forms of Msp. The invention also relates to nucleic acid characterization using Msp.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: September 5, 2017
    Assignee: Oxford Nanopore Technologies Ltd.
    Inventors: James Clarke, Andrew John Heron, Lakmal Jayasinghe, Elizabeth Jayne Wallace, James White
  • Patent number: 9731005
    Abstract: A pharmaceutical composition for its use in the prophylactic treatment of a patient against an intracellular pathogen, said composition comprising a solid nanoparticle comprising a porous cationic-polysaccharide solid core, loaded with at least an anionic phospholipid, without said cationic-polysaccharide core being surrounded by any phospholipidic layer, and at least an antigen obtained from said pathogen.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: August 15, 2017
    Assignees: UNIVERSITE DE DROIT ET DE SANTE DE LILLE II, UNIVERSITE DE TOURS FRANCOIS RABELAIS, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE
    Inventors: Didier Betbeder, Isabelle Dimier-Poisson, Céline Ducournau
  • Patent number: 9708369
    Abstract: Disclosed are methods of altering metabolism of phosphate in a livestock via an antibody. The methods involve the development of an antibody against FGF-23 for the purpose of reducing phosphate excretion by an animal.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: July 18, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Mark E. Cook, Elizabeth A. Bobeck, Kimberly S. Burgess
  • Patent number: 9693578
    Abstract: The present invention relates to a method of producing a probiotic fruit beverage comprising a high viable count of acid-adapted probiotic bacteria, such as strains of Lactobacillus paracasei subsp. paracasei, and to probiotic fruit beverage obtainable by such method.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: July 4, 2017
    Assignee: Chr. Hansen A/S
    Inventors: Tina Hornbaek, Caroline Trebbien Gottlieb, Tina Malling Thorsen, Peter Sommer
  • Patent number: 9675682
    Abstract: The present invention provides attenuated M. haemolitica strains that elicit an immune response in animal against M. haemolitica, compositions comprising said strains, methods of vaccination against M. haemolitica, and kits for use with such methods and compositions. The invention further provides multi-valent vaccines, which provide protective immunity when administered in an effective amount to animals susceptible to “shipping fever” or bovine respiratory disease.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: June 13, 2017
    Assignee: MERIAL, INC.
    Inventors: Russell F. Bey, Paulraj Kirubakaran Lawrence, Randy R. Simonson
  • Patent number: 9650639
    Abstract: Provided herein are recombinant Listeria strains expressing a tumor-specific antigenic polypeptide and, optionally, an angiogenic polypeptide wherein a nucleic acid molecule encoding at least one of the polypeptides is operably integrated into the Listeria genome in an open reading frame with a nucleic acid sequence encoding a PEST-containing polypeptide, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: May 16, 2017
    Assignee: ADVAXIS, INC.
    Inventors: Paulo Maciag, Anu Wallecha, Vafa Shahabi
  • Patent number: 9624275
    Abstract: Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: April 18, 2017
    Assignees: University of Washington, The UAB Research Foundation
    Inventors: Jens H. Gundlach, Michael Niederweis, Thomas Z. Butler, Mikhail Pavlenok, Mark A. Troll, Suja Sukumaran
  • Patent number: 9610336
    Abstract: Diseases caused by a spirochete bacteria are treated. Doses of an anti-flagellin monoclonal antibody, spirochetal protein, or Lyme lysate are used in predetermined increasing doses to effectively treat diseases and symptoms caused by spirochete bacteria, and in particular Lyme disease.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: April 4, 2017
    Inventor: Amiram Katz
  • Patent number: 9605035
    Abstract: The present invention concerns VLPT immunoreactive compositions for E. chaffeensis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. chaffeensis VLPT are disclosed.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: March 28, 2017
    Assignee: Research Development Foundation
    Inventors: Jere W. McBride, Tian Luo
  • Patent number: 9606252
    Abstract: This disclosure is related to marine seismic sources, for example marine seismic sources known in the art as benders. Some embodiments of this disclosure use magnetic reluctance forces to produce seismic energy. For example, pole pieces may be attached to one or more plates of a marine seismic source, and a wire coil may induce an attractive force between the pole pieces to cause deformation of the plates to produce seismic energy. Such marine seismic sources may be components of a marine seismic survey system, and may be used in a method of marine seismic surveying. Methods of making marine seismic sources are also disclosed.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: March 28, 2017
    Assignee: PGS Geophysical AS
    Inventors: Mattias Oscarsson, Oeystein Traetten, Rune Voldsbekk, Rune Toennessen
  • Patent number: 9597372
    Abstract: The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: March 21, 2017
    Assignees: The Regents of the University of California, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Leonard H. Rome, Valerie A. Kickhoefer, Steven M. Dubinett, Sherven Sharma, Upendra K. Kar
  • Patent number: 9535064
    Abstract: Assays for detecting anti-streptococcal antibodies in biological samples using one or more streptococcal antigens are described herein. Various combinations of antigens may be used in the assays. For example, one or more of Ply, PhtD, PhtE, LytB and PcpA may be utilized. Additional streptococcal antigens may also be used. The assays may also be used in combination with assays that detect streptococcal nucleic acids.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: January 3, 2017
    Assignee: SANOFI PASTEUR LIMITED
    Inventors: Martina Ochs-Onolemhemhen, Roger Brookes, Claire-Anne Siegrest
  • Patent number: 9534024
    Abstract: Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: January 3, 2017
    Assignees: THE UAB RESEARCH FOUNDATION, UNIVERSITY OF WASHINGTON
    Inventors: Jens H. Gundlach, Michael Niederweis, Thomas Z. Butler, Mikhail Pavlenok, Mark A. Troll, Suja Sukumaran
  • Patent number: 9487564
    Abstract: The present invention provides isolated polypeptides isolatable from a Fusobacterium spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: November 8, 2016
    Assignee: EPITOPIX, LLC
    Inventors: Darren E. Straub, Daryll A. Emery
  • Patent number: 9474795
    Abstract: Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: October 25, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Che-Hung Robert Lee, Carl E. Frasch
  • Patent number: 9469849
    Abstract: Methods and systems for chromatographically purifying a botulinum neurotoxin are provided. These methods and systems allow for efficient purification of a non-complexed form of the botulinum neurotoxin in high purity and yield that can be used as an active ingredient in pharmaceutical preparations.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: October 18, 2016
    Assignee: Revance Therapeutics, Inc.
    Inventor: Curtis L. Ruegg
  • Patent number: 9463231
    Abstract: The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: October 11, 2016
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Jeremy Kroll, Mike Roof
  • Patent number: 9415077
    Abstract: Described herein are compositions, vaccines, and methods that include use of a mutated Bordetella strain against allergic diseases such as asthma and skin inflammation. Also described are kits. Other compositions, vaccines, and methods are also described.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: August 16, 2016
    Assignees: Institut National de la Sante et de la Recherche Medicale, Institut Pasteur de Lille, National University of Singapore
    Inventors: Sylvie Claudette Alonso, Rui Li, Camille Locht